Show simple item record

dc.contributor.authorBygrave, C
dc.contributor.authorPawlyn, C
dc.contributor.authorDavies, F
dc.contributor.authorCraig, Z
dc.contributor.authorCairns, D
dc.contributor.authorHockaday, A
dc.contributor.authorJenner, M
dc.contributor.authorCook, G
dc.contributor.authorDrayson, M
dc.contributor.authorOwen, R
dc.contributor.authorGregory, W
dc.contributor.authorMorgan, G
dc.contributor.authorJackson, G
dc.contributor.authorKaiser, M
dc.date.accessioned2020-07-03T11:19:35Z
dc.date.issued2020-06-10
dc.identifier.citationBritish journal of haematology, 2020
dc.identifier.issn0007-1048
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3793
dc.identifier.eissn1365-2141
dc.identifier.doi10.1111/bjh.16793
dc.description.abstractPredicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse within 12 months of autologous stem cell transplant was associated with markedly worse median progression-free survival 2 (PFS2) of 18 months and overall survival (OS) of 26 months, compared to median PFS2 of 85 months and OS of 91 months for later relapsing patients despite equal access to and use of subsequent therapies, highlighting the urgent need for improved outcome prediction and early intervention strategies for myeloma patients.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleEarly relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
dc.typeJournal Article
dcterms.dateAccepted2020-05-05
rioxxterms.versionofrecord10.1111/bjh.16793
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-06-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of haematology
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamMyeloma Biology and Therapeuticsen_US
icr.researchteamMyeloma Groupen_US
dc.contributor.icrauthorPawlyn, Charlotteen
dc.contributor.icrauthorKaiser, Martinen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0